Atypical Antipsychotic-Induced Parkinsonism: A Patient Case with CYP Enzyme Implications by Figura, Carla Dolci & Schuh, Michael
Volume 8 | Number 2 Article 2
4-11-2017
Atypical Antipsychotic-Induced Parkinsonism: A
Patient Case with CYP Enzyme Implications
Carla Dolci Figura
University of Florida, carla.d.figura@gmail.com
Michael Schuh
University of Florida, schuh.michael@mayo.edu
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Figura CD, Schuh M. Atypical Antipsychotic-Induced Parkinsonism: A Patient Case with CYP Enzyme Implications. Inov Pharm.
2017;8(2): Article 2. http://pubs.lib.umn.edu/innovations/vol8/iss2/2
Clinical Experiences PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                        2017, Vol. 8, No. 2, Article 2                          INNOVATIONS in pharmacy   1 
 
 
Atypical Antipsychotic-Induced Parkinsonism: A Patient Case with CYP Enzyme Implications 
Carla D. Figura, PharmD Candidate1; Michael J. Schuh, PharmD2 
1University of Florida College of Pharmacy, Gainesville Campus; anticipated completion of studies: 2018; 
 2Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy 
 
Abstract 
Objective: To report a case of Parkinsonism potentially caused by neuroleptic medications. Summary: The case analyzed is that of a 
57-year-old male patient referred to a pharmacotherapy service by a neurologist after organic causes of tremor had been ruled out. 
Iatrogenic cause was suspected and referral expectation was to identify the offending agent or agents and propose alternative therapy. 
Conclusion:  This case illustrates iatrogenic risk associated with neuroleptic medications while illustrating mechanisms of drug 
interaction via CYP enzymes that can lead to iatrogenic disease.  
 
Abbreviations: DIP = Drug-induced Parkinsonism; MTM = Medication Therapy Management; PD = Parkinson’s Disease 
Keywords: Drug-induced Parkinsonism, Parkinsonism, Neuroleptic Medication, Medication Therapy Management, Pharmacotherapy 
 
 
Introduction 
Parkinson’s Disease (PD) is currently the second most common 
neurodegenerative disease affecting our population today;1 as 
many as 14/100,000 in the general population, and 160 cases 
per 100,000 in individuals age 65 or greater.2 There are many 
proposed risk factors for PD, including high amounts of dairy  
consumption, exposure to pesticides, brain injury, over-
exposure to vitamins and minerals, among others.2 PD often 
presents itself in the form of resting tremor, dyskinesia, 
stiffness, and postural instability. The root cause of these 
symptoms is the same – a loss of dopamine in the CNS needed 
for neuronal firing. Parkinson’s Disease cannot be reversed, 
however progression can be slowed by the use of anti-
Parkinson’s agents. Unfortunately, it is not uncommon for 
reversible causes of diminished dopamine to be misdiagnosed 
as Parkinson’s Disease. This case study analyzes a case of 
Parkinsonism induced by neuroleptic medications. Drug-
induced Parkinsonism (DIP) is the second leading contributor to 
Parkinson-like symptoms, second only to true Parkinson’s 
Disease. Consideration of iatrogenic causes of Parkinson-like 
symptoms can have a life changing effect for patients in the 
form of returned mobility status, cessation of tremor, and 
improved quality of life. 
 
Setting 
 The practice setting is a multispecialty, tertiary care clinic 
located in Florida. The clinic offers pharmacist-provided       
MTM, including more advanced pharmacotherapy services to 
all patients in the clinic via referral from physicians and           
other providers with ordering privileges. The pharmacist 
pharmacotherapy service sees patients from more than 20 
different departments and is considered a specialty service, 
similar to other specialty services within the clinic. 
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Case Report 
Our subject is a 57 year-old white male presented to his 
neurology physician because his wife noticed a considerable   
change in mental status. He had been seeing “demons” at 
church, had lost his ability to do simple math (seen by difficulty 
tipping), and had lost his general sense of direction, often 
getting lost while driving. Our patient’s medical history includes 
bipolar depression, loss of memory, recent onset tremor, 
hyperlipidemia, and history of head trauma. Because many of 
these symptoms had recent, sudden onset, his wife was 
concerned. Neurologic exam revealed bradykinesia, mild nuchal 
rigidity, increased tone in upper limbs, slight tremor, and slight 
anterocollis, stooped gait with decreased arm swing. See Table 
1 for a list of his medications at presentation. 
 
Upon evaluation by his neurological provider, our patient was 
found to have an incipient neurodegenerative process, likely 
due to a distant history of head trauma. His mother also had a 
history of severe depression and early-onset Alzheimer’s 
Disease; this indicates that his psychological and behavioral 
issues may have a genetic component. While an iatrogenic 
contribution to his memory loss, dyscalculia, and 
dysgraphesthesia were possible, organic causes were not the 
only concern of the provider at this time. His tremor, however, 
did not fit the traditional presentation of organic tremor. It was 
subtle, and varied in severity over time. The neurology provider 
suspected iatrogenic cause of tremor, and referred this patient 
to our service. Both prescription and over-the-counter 
medications were reviewed for adherence, and their side effect 
profiles assessed for possible iatrogenic cause (Table 2).   
 
By analyzing his medications, their receptor binding activity, 
and effects on dopamine, we were able to identify recent 
changes in his medications that correlated well with his recent 
onset tremor (Table 2). 
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Topiramate. Topiramate is a weak inducer of CYP3A4.11 His 
total daily dose has recently decreased due to the dosing 
interval being changed from three times a day to two times a 
day.  
 
Quetiapine. Quetiapine is a CYP3A4 substrate,9 and acts in part 
as a prodrug converting dopamine affinity quetiapine to more 
5-hydroxytriptophan affinity norquetiapine.10  Since the 
inducing effects of topiramate were recently reduced (less 
doses given per day), but the quetiapine dose was not changed, 
the quetiapine was now likely being converted from the 
dopamine blocking compound more slowly, producing more 
dopamine inhibiting effects.9-10 Quetiapine, an atypical 
antipsychotic, does have reports of causing DIP, although much 
less commonly than other agents.1 
 
Brexpiprazole. Brexpiprazole is also a CYP3A4 substrate.6 The 
brexpiprazole was initiated at the same time that the 
topiramate total daily dose was reduced; because of this, the 
brexpiprazole was not being cleared at the anticipated rate, and 
may have been accumulating. Brexpiprazole is also an atypical 
antipsychotic; it is a cousin of a common DIP-offender, 
aripirazole.1 Brexpiprazole has a history of reported 
Parkinsonism, and is a likely offender in our patient.14 
 
Divalproex. Our patient was also taking divalproex, a weak 
inhibitor of CYP3A4.7 This may also have been contributing to 
an accumulation of brexpiprazole.  
 
Lithium. Lithium is not metabolized through the CYP450 
system,8 making interactions with the above medications highly 
unlikely. Additionally, no recent changes had been made to his 
lithium dose, making contributions of lithium to his recent 
tremor highly unlikely. 
 
Multiple interventions were suggested by our service to reverse 
the effects of DIP: 
• A trial discontinuation of one antipsychotic is 
warranted. Maximization of one agent should be 
considered before addition of another medication in 
this case. 
• Since brexpiprazole is a possible major contributor, 
slowly taper off and discontinue. 
• Quetiapine is not currently optimized to a maximum 
daily dose of 800 mg. If needed upon discontinuation of 
brexpiprazole, titrate dose slowly upward to 800 mg 
daily. 
• Resolution of symptoms from DIP may take up to 18 
months to resolve. If after this time symptoms have not 
subsided, consider alternative therapy to divalproex, to 
remove the CYP3A4 inhibition. Instead, consider 
alternative lamotrigine, which is metabolized by UGT.  
At this time, the patient has not had a follow-up appointment 
with neurology for a final assessment of his case, so it is not yet 
possible to evaluate the effectiveness of this recommendation 
for alleviation of his symptoms. The patient is scheduled for 
4/26/17 for return. 
   
Parkinsonism vs. Parkinson’s Disease 
Both Parkinson’s Disease and Parkinsonism can cause tremors, 
stiffness, slow movement, and postural instability that are 
commonly associated with PD.3 These symptoms are a result of 
a loss of dopamine, which is why the two disorders present 
similarly, often indistinguishable until severe progression of the 
disease has taken place. Because of the shared pathophysiology 
of the symptoms, there is not a diagnostic test that is helpful in 
differentiating between the two disorders (ex: Dopamine 
Transporter – DaT – Test).1 The difference between these two 
presentation lies in the reason for the loss of dopamine. 
 
Parkinson’s Disease generally progresses slowly, and is 
commonly coupled with depression, loss of smell, cognitive 
decline, and/or gastric problems.4 Parkinsonism, on the other 
hand, generally has a sudden onset, and can be associated with 
more severe symptoms such as falling, hallucinations, and 
dementia-like cognitive defects.3 Our patient had these, 
including the hallucination of seeing demone in church. A 
patient experiencing Parkinsonism may not respond to 
traditional Levodopa therapy the way a PD patient would.5 
There are many different causes of Parkinsonism, including: 
drug-induced Parkinsonism, progressive supranuclear palsy, 
multiple-system atrophy, vascular Parkinsonism, dementia with 
Lewy bodies, and corticobasal degeneration.3  
 
Drug-Induced Parkinsonism 
Drug-induced Parkinsonism (DIP) is the 2nd most common 
etiology of Parkinsonism, second only to Parkinson’s Disease.3 
Some common classes of DIP culprits include typical 
antipsychotics, atypical antipsychotics, dopamine depleters, 
anti-emetics, and calcium channel blockers. Extrapyramidal 
symptoms are common among patients using antipsychotic 
medications because of their effects on dopamine receptors in 
the brain.1 Although presentation of  DIP generally occurs 
within weeks of beginning therapy with the offending 
antipsychotic, presentation months after initiation is not 
unlikely. 
 
Many of the movement disorders seen in DIP are the same as 
PD, but may be more sudden and severe in nature. Fortunately, 
upon discontinuation of the offending agent, the movement 
disorders associated with DIP will usually subside. It is 
important to note, however, that restoration of normal 
dopamine levels can take up to 18 months, and therefore, it is 
not appropriate to consider treatment of the movement 
disorders for at least 18 months after discontinuation of the 
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anticipated offending agent.3 It is also possible that the patients 
may have been in a preclinical state of PD, and the use of these 
medications simply unmasked the underlying disease; there is a 
chance that the effects may not subside once this point is 
reached, even upon discontinuation of the offending agent.1 
Only after adequate time has passed after discontinuation of 
any possible offending agents is it reasonable to consider the 
use of anti-PD medications. 
 
Discussion 
This patient was referred to our service by his neurologist within 
our healthcare system. Generally, when a patient is referred to 
our service, it is after evaluation by a diagnostic provider who 
deems deeper evaluation of medication therapy to be a 
necessity for the patient and after other diagnostic testing is 
negative.  
 
As noted in the patient case, DIP is an issue suffered by 
thousands of patients annually. Through collaborative practices 
and thorough evaluation, healthcare teams can work together 
to eliminate misdiagnoses like these and improve the quality of 
life of thousands of patients every year.  
 
There is an expansive role for pharmacists in the realm of 
Medication Therapy Management. Complicated patients 
present to health care providers every day, and there is no 
provider better equipped with the knowledge or resources to 
resolve complicated medication related problems (MRPs) than 
a practicing clinical pharmacist due to their extensive training in 
pharmacology, biochemistry, pathophysiology of medicine, and 
pharmacotherapy. 
 
Case Summary 
The patient presented with tremor thought to be iatrogenic in 
nature, as evaluated by his neurologist. Upon evaluation by our 
service, he was found to have three possible contributing 
components to his symptoms: recent increase in dosing interval 
and lower dose of topiramate, an inducer of CYP3A4; recent 
initiation of brexpiprizole, a CYP3A4 substrate and likely 
offender of his DIP; and quetiapine, an agent unlikely to cause 
DIP, although cases have been reported. His quetiapine use was 
longstanding and no recent changes had occurred. The 
recommendation by our service was to discontinue the recently 
initiated brexpiprazole, and titrate the quetiapine dose up as 
necessary, not to exceed a maximum daily dose of 800 mg. 
 
Conclusion 
By raising awareness of Drug-induced Parkinsonism and other 
causes possible causes of Parkinsonism, health care providers 
can avoid unnecessary reductions in quality of life for sufferers 
and avoid unnecessary therapies. Consideration of possible 
iatrogenic causes of Parkinson-like symptoms is important to 
eliminate possible misdiagnoses of PD, unnecessary treatment, 
and suffering for patients. This can be accomplished by 
collaborating as an interdisciplinary health care team, keeping 
the patient at the center of all decision-making, and considering 
all possible causes before reaching a definitive diagnosis such as 
Parkinson’s Disease. This includes analysis of pharmacokinetics, 
pharmacogenomics testing results, side effect profiles of all 
medications, and simplified treatment regimens for patients to 
improve patient treatment outcomes and quality of life. 
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Table 1: Medications at the Time of Pharmacotherapy Visit 
 
Medication Dose Time/frequency Indication 
Brexpiprazole 1 mg 1 tab PO Daily Depression 
Cholecalciferol (Vitamin D3) 2000 IU 1 tab PO Daily Vitamin D Deficiency 
Divalproex sodium 250 mg 3 tabs PO BID daily Bipolar Depression 
Esomeprazole 40 mg 1 cap PO daily GERD 
Fluticasone nasal spray  50 mcg 1 puff nasally daily Allergic Rhinitis 
Levothyroxine 112 mcg 1 tab PO daily Hypothyroidism 
Lisinopril 10 mg 1 tab PO daily HTN 
Lithium Carbonate  300 mg 2 tabs PO daily Bipolar Disorder 
Botox - As directed every 12 weeks Migraines 
Phenylephrine 10 mg 1 tab PO BID Congestion 
Quetiapine 600 mg 2 tabs PO daily Anti-psych 
Simvastatin 40 mg 1 tab PO daily HLD 
Topiramate 200 mg 1 tab PO daily Migraines 
OTC Medications 
Excedrin Migraine  - 2 tabs PO PRN  Headache 
Aspirin 81 mg 1 tab PO daily Antiplatelet 
Multivitamin - 1 PO daily General health 
 
 
 
 
 
 
Table 2: Rationale for Iatrogenic Presentation 6-11 
 
Drug Recent 
Change 
CYP 450 
Activity 
Dopamine 
Receptor 
Activity 
Occurrence of Pseudo-
parkinsonism 
Net Effect 
Brexpiprazole Added 3A4 
substrate 
D2 partial 
agonist 
Uncommon; usually within 2 
weeks of initiation 
Direct decrease in dopamine 
activity 
Divalproex 
Sodium 
No change Weak 
inhibitor 
3A4 
- Uncommon Increased exposure to 
neuroleptic agents Indirect 
decrease in dopamine activity  
Quetiapine No change 3A4 
substrate 
D1 antagonist 
D2 antagonist 
~6% Direct decrease in dopamine 
activity 
Topiramate Decreased 
daily dose 
and dosing 
interval 
Weak 
inducer 3A4 
- Not reported Increased exposure to 
neuroleptic agents Indirect 
decrease in dopamine activity   
DA = dopamine, D1 = dopamine 1 receptor, D2 = dopamine 2 receptor 
 
